Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-552 in Mild Alzheimer's Disease (Japan)
jRCT2071230035Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of SDI-118 in Alzheimer's disease (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change in ADAS-Cog 14 score. Started Jun 2023; status: active, not recruiting.
02
Drugs
SDI-118
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2071230035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230035.